Percutaneous Ultrasound-guided "Three-step" Radiofrequency Ablation for Giant Hepatic Hemangioma
NCT ID: NCT04131153
Last Updated: 2019-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
106 participants
INTERVENTIONAL
2013-06-01
2019-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study was to evaluate the safety, feasibility and efficacy of the new radiofrequency ablation (" three-step "radiofrequency ablation) in the treatment of giant hepatic hemangioma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Controlled Study on Treatment of Giant Cavernous Hemangiomas of the Liver
NCT01471080
No-touch Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma Using Triple Cooled-Wet Electrodes
NCT05449873
Effectivity and Safety of Ultrasound-guided Percutaneously Radiofrequency Ablation for Liver Cancer
NCT03026452
Added Value of Contrast-enhanced Ultrasonography for Percutaneous Radiofrequency Ablation
NCT05445973
Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma With Twin Cooled-wet Electrodes
NCT05449860
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
.Other alternative therapies, such as transcatheter arterial embolization, radiotherapy and steroid therapy, have also been reported for the treatment of hepatic hemangioma, but the efficacy is not satisfactory .
Percutaneous ultrasound-guided radiofrequency ablation is a safe and minimally invasive treatment with reliable efficacy. In recent years, this technique has been successfully applied in the treatment of hepatic hemangioma with a diameter of \< 5cm.For huge liver hemangioma, however, need to use the conventional radiofrequency ablation can increase one-time ablation volume of radiofrequency electrode or enhance ablation power and extend the melting time, not only bring patients suffering discomfort, but easy to damage the adjacent organs, causing serious complications such as hemorrhage, perforation of gastrointestinal tract, acute renal failure .Therefore, the investigators have developed a new,standardized radiofrequency ablation for giant hepatic hemangioma to shorten the duration of treatment, reduce surgical complications and improve the surgical success rate.
The purpose of this study was to evaluate the safety, feasibility and efficacy of the new radiofrequency ablation (" three-step "radiofrequency ablation) in the treatment of giant hepatic hemangioma.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Conventional radiofrequency ablation group
Conventional radiofrequency ablation procedures
radiofrequency ablation
Conventional radiofrequency ablation
Three-step radiofrequency ablation group
After destroying the main blood supply of the tumor, extracting the blood in the tumor, reducing the blood flow in the tumor and shrinking the tumor volume, the remaining tumor was then treated with radiofrequency ablation, namely the "three-step" radiofrequency ablation with "one block, two inhalation and three damages".
"three-step" radiofrequency ablation
After destroying the main blood supply of the tumor, extracting the blood in the tumor, reducing the blood flow in the tumor and shrinking the tumor volume, the remaining tumor was then treated with radiofrequency ablation, namely the "three-step" radiofrequency ablation with "one block, two inhalation and three damages".
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
"three-step" radiofrequency ablation
After destroying the main blood supply of the tumor, extracting the blood in the tumor, reducing the blood flow in the tumor and shrinking the tumor volume, the remaining tumor was then treated with radiofrequency ablation, namely the "three-step" radiofrequency ablation with "one block, two inhalation and three damages".
radiofrequency ablation
Conventional radiofrequency ablation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The Child-Pugh grade A/B;
3. The ICG15 20% or less;
4. The eCOG score was 0;
5. The patients was persistent hemangioma-related abdominal pain or discomfort, and it has clear exclusion of other gastrointestinal diseases causing upper abdominal pain by gastroscopy;
6. The patients refused to receive surgical treatment, but agreed to receive radiofrequency ablation;
7. There were no other related diseases affecting RFA treatment.
Exclusion Criteria
2. Severe primary organ failure, such as liver, kidney, heart, lung or brain;
3. Severe bleeding tendency, platelet count \< 50 ×10\^9/L, or prothrombin time extension \> 18s;
4. Previous treatment of hepatic hemangioma (TACE, steroids, etc.).
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Southwest Hospital, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
fengkai
Principal Investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20180407
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.